Transcenta Holding Limited

6628

KYG9005B1041

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 EDT			5-day change	1st Jan Change
1.78 ^HKD	+1.14%		-1.66%	-50.42%

05-24	Transcenta Shows 'Encouraging' Data from Gastric Cancer Combination Drug Trial	MT
05-24	Transcenta Holding Limited Announces Updates of Phase II Data from First-Line Triple Combination Trial of Osemitamab for G/GEJ Cancer at ASCO 2024	CI

Tranche Update on Transcenta Holding Limited's Equity Buyback Plan announced on September 14, 2022.

April 27, 2023 at 05:42 am

From September 14, 2022 to December 31, 2022, the company has repurchased 1,899,500 shares, representing 0.43% for HKD 7.26 million. With this, the company has completed the repurchase of 1,899,500 shares, representing 0.43% for HKD 7.26 million under the buyback announced on September 14, 2022.

Latest news about Transcenta Holding Limited

Transcenta Shows 'Encouraging' Data from Gastric Cancer Combination Drug Trial	05-23	MT
Transcenta Holding Limited Announces Updates of Phase II Data from First-Line Triple Combination Trial of Osemitamab for G/GEJ Cancer at ASCO 2024	05-23	CI
Transcenta Holding Limited Announces Board and Nomination Changes	04-30	CI
Transcenta Partners with Agilent to Develop Claudin18.2 Companion Diagnostic	04-09	MT
Transcenta Holding Limited Announces Collaboration with Agilent Technologies to Develop a Claudin18.2 Companion Diagnostic to Support TranStar301 Global Phase III Trial	04-08	CI
Transcenta Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Transcenta Publishes Promising Results of Anti-Tumor Drug's Efficacy and Safety in European Journal	12-13	MT
Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging	12-13	CI
Transcenta Presents Data on Gastric/Gastroesophageal Cancer Treatment Trial at Spain Oncology Meet	23-10-23	MT
Transcenta Holding Limited Presents Updated Efficacy Data from the Expansion Cohort of the Transtar102 of Osemitamab Plus Capox Chemotherapy Study as the First-Line Treatment of Advanced G/Gej Cancer At the ESMO Congress 2023 in Madrid, Spain	23-10-23	CI
US FDA Approves Phase 3 Trial for Transcenta's Gastric Cancer Treatment	23-10-03	MT
FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients	23-10-03	CI
Transcenta Widens Loss in H1	23-08-23	MT
Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023	23-08-22	CI
Transcenta Holding Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22	CI
Transcenta Moves to Phase II Trial of Osteoporosis Drug	23-07-31	MT
Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)	23-07-30	CI
China, South Korea Approve Transcenta's Phase 3 Trial for Anti-Tumor Medication	23-07-07	MT
Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab	23-07-07	CI
Transcenta Holding Limited Presents Pfs Data by Cldn18.2 Expression Level from Phase I/Ii Study of Osemitamab Plus Capecitabine and Oxaliplatin as the First-Line Treatment of Advanced G/Gej Cancer	23-06-30	CI
Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin	23-06-30	CI
Transcenta Holding Limited commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on June 9, 2023.	23-06-09	CI
Transcenta Holding Limited's Equity Buyback announced on September 14, 2022, has expired.	23-06-08	CI
Transcenta Presents Data on Gastric Cancer Treatment at US Oncology Meeting	23-06-05	MT
Transcenta Holding Limited Presents Updated Data of Cohort C from Phase I/IIa, Multi-Center Study of Osemitamab	23-06-05	CI

Chart Transcenta Holding Limited

Duration

Period

More charts

Company Profile

Transcenta Holding Limited is a China-based investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. The Company's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The Company's all products are in the research and development (R&D) stage and have not been commercialized. The Company also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Transcenta Holding Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.648 CNY

Average target price

7.58 CNY

Spread / Average Target

+359.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TRANSCENTA HOLDING LIMITED	-50.42%	91.32M
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B

Other Pharmaceuticals

Transcenta Holding Limited

Equities

6628

KYG9005B1041

Pharmaceuticals

Tranche Update on Transcenta Holding Limited's Equity Buyback Plan announced on September 14, 2022.

EPS Revisions